Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of “Buy” by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $12.25.

Several research analysts have recently commented on IMUX shares. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a report on Monday, September 16th. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Leerink Partners restated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Finally, B. Riley initiated coverage on shares of Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target for the company.

Insider Activity

In other news, Director Richard Alan Rudick bought 87,300 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now owns 87,300 shares in the company, valued at approximately $100,395. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the last quarter. BVF Inc. IL bought a new position in shares of Immunic during the first quarter valued at $11,752,000. Janus Henderson Group PLC bought a new position in shares of Immunic during the first quarter valued at $9,266,000. Ikarian Capital LLC boosted its position in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Immunic in the 1st quarter worth about $25,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Stock Down 0.9 %

Shares of NASDAQ:IMUX opened at $1.10 on Friday. The company’s fifty day moving average is $1.40 and its 200 day moving average is $1.34. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The stock has a market cap of $99.09 million, a PE ratio of -0.89 and a beta of 1.88.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.